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Aim: To investigate the effect of time of day of dosing (morning or evening) on lung function
following administration of fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg.
Methods: Double-blind, placebo-controlled, randomised, three-way crossover study. Subjects
with persistent asthma (N Z 26) received FF/VI (morning or evening) or matching placebo
once-daily for 14 (2 days) via dry powder inhaler (DPI). Weighted mean (0e24h) and pre-
treatment FEV1 (morning and evening) were determined after the Day 14 evening dose, together
with mean pre-treatment (morning and evening) peak expiratory flow (PEF) on Days 2e12.
Results: FF/VI 100/25 administered morning or evening produced clinically significant increases
in weightedmean FEV1: the differences [95% confidence interval (CI)] from placebo were 377mL
[293, 462] and 422 mL [337, 507], respectively; the difference between morning and evening
dosingwas44mL [125, 36]. Day 14 pre-treatmentmorning FEV1 differences [95% CI] from pla-
cebo were 403 mL [272, 533] and 496 mL [369, 624] after morning and evening dosing, respec-
tively; the morning:evening treatment difference was 94 mL [221, 34]. Pre-treatment
evening FEV1 differences [95% CI] from placebo were 275mL [169, 380] and 309mL [205, 413] af-
ter morning and evening dosing, respectively; the morning:evening treatment difference was
34 mL [138, 70]. FF/VI (morning or evening) produced rapid increases in PEF with the fulliscovery and Development, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK. Tel.: þ44 (0) 1438 76
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1874 R.D. Kempsford et al.effect apparent after the first dose and maintained throughout the 14-day treatment period.
Conclusion: FF/VI 100/25 produces comparable improvements in lung functionwhether dosed in
the morning or evening in subjects with persistent asthma.
[GSK protocol HZA114624, NCT01287065].
ª 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Introduction
International guidelines advocate the use of an inhaled
corticosteroid combined with a long-acting beta-agonist
(ICS/LABA) for the maintenance therapy of asthma patients
who remain symptomatic despite use of low-medium dose
ICS alone [1,2]. Currently available ICS/LABA treatments
(fluticasone propionate (FP)/salmeterol, budesonide/for-
moterol and mometasone furoate/formoterol) are admin-
istered twice daily [3e5]. Simplifying the dosing regimen to
once daily, particularly for chronic conditions such as
asthma may improve compliance and disease management,
providing sustained 24-h bronchodilation and bronchopro-
tection [6e9].
Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Pow-
der is a once-daily ICS/LABA combination for the treatment
of asthma and COPD. When delivered via a dry powder
inhaler (DPI), FF/VI has demonstrated a good safety and
tolerability profile with improvements in lung function in
asthma [10e12] and COPD patients [13,14].
Considerable evidence exists to support the concept
that asthma is influenced by circadian rhythms, with
symptoms worsening and lung function decreasing at night
[15e19]. Given this chronobiology of asthma, it is not sur-
prising that time of administration has been shown to in-
fluence the efficacy of some bronchodilators with once-
daily dosing in the evening potentially being the most
effective treatment paradigm [15,18e21]. These time
dependent effects of corticosteroid administration have
been seen in asthma with evening dosing proving the most
effective time for some once-daily ICS formulations with
respect to lung function and reduction of side-effects
relating to cortisol suppression [22e25]. Previous data
have shown once-daily evening dosing with FF 400 mcg to
be as effective as twice-daily dosing with FF 200 mcg [22]
and therefore, FF/VI has been dosed in the evening
across the Phase II and Phase III asthma development pro-
gramme [10e12]. Individual patients may prefer to choose
what time of day they take their medication. Therefore,
having the flexibility of dosing either in the morning or
evening may be more convenient for the patient and may
further improve treatment adherence and the management
of asthma symptoms.
The potential effects of altering the time of day of
dosing of FF/VI have not been previously explored. There-
fore, the current study directly compared the effect of
morning and evening dosing of FF/VI 100/25 mcg on lung
function over 24 h in subjects with persistent bronchial
asthma. FF/VI 100/25 contains the optimal dose of each
component for patients uncontrolled on low-medium dose
ICS and will probably be the most widely used clinical dose.Methods
Subjects
Healthy non-smokers (i.e. not smoked within past 12
months; pack history 10 pack years), aged 18e70 years
(inclusive) with a body mass index (BMI) within range
19.0e29.9 kg/m2 were included. Females were of non-
childbearing potential (i.e. post-menopausal or surgically
sterile) or using protocol-specified contraception. Subjects
had a documented history of persistent asthma treated
with an ICS with or without a short-acting beta-agonist
(SABA) for at least 12 weeks prior to screening, a best pre-
bronchodilator FEV1 60% predicted, (predicted values
were based on NHANES III) [26] and reversibility FEV1 12%
over baseline and absolute change 200 mL (10e30 min
after a SABA). Subjects were clinically stable on an ICS dose
(fluticasone propionate [FP] at 100e250 mcg twice-daily
[total daily dose 200e500 mcg] or equivalent ICS) within
the 4 weeks preceding screening. Subjects with significant
abnormalities in the 12-lead electrocardiogram (ECG), vital
signs or clinical laboratory assessments at screening were
excluded. Subjects were excluded if they had any asthma
exacerbation requiring oral corticosteroids within 12 weeks
or hospitalisation within 6 months prior to screening or they
had taken high doses of ICS (FP > 250 mcg twice-daily [total
daily dose >500 mcg FP or equivalent]) within 8 weeks of
screening or oral steroids within 12 weeks of screening or
they had an unresolved respiratory infection within 4 weeks
before screening which led to a change in asthma man-
agement or status..Study design
This was a randomised, double-blind, placebo-controlled,
three-way crossover study conducted between October
2010 and September 2011 at a single site (P3 Research Ltd,
New Zealand). The study was conducted in accordance with
the Declaration of Helsinki and approved by an independent
ethics committee prior to the start of the study. Informed
consent was obtained prior to any study procedures. A
study schematic is provided in Fig. 1. Subjects received
three different treatments administered by oral inhalation
via DPI and were dosed twice daily to maintain the blind
(Table 1). FF/VI doses or placebo were administered at
approximately 09:00 and 21:00. Dosing started with the
evening dose on Day 1. Subjects were dosed for 14  2 days
i.e. the timing of Day 14 was flexible and could take place
within 2 days of the actual Day 14 time point. The
24-h assessment period started at the evening dosing time
Figure 1 Study schematic illustrating the study design and treatment sequences.
Morning versus evening administration of FF/VI 1875on Day 14. Day 15 was always the 24-h period after Day 14.
The central randomisation schedule was generated by GSK
Quantitative Sciences using validated internal software.
The investigator or designee received the medication
assignment information and randomised subjects using
sequentially numbered containers.Assessments
Efficacy
Lung function (forced expiratory volume in 1 s [FEV1] and
peak expiratory flow [PEF]) was measured throughout the
study. FEV1 measurements were made in accordance with
the American Thoracic Society (ATS)/European Respiratory
Society (ERS) guidelines [27]. FEV1 was recorded electron-
ically at screening (between 17:00 and 23:00) and on Day 1
(pre-evening dose) and Day 14 (every 3 h for 0e24 h i.e.
from approximately 21:00 on Day 14 until 21:00 on Day 15).
All evening FEV1 measurements were within 1 h of the
screening FEV1 measurement. Subjects measured their PEFTable 1 Summary of treatment regimens.
Treatment
regimen
Morning
inhalation
Evening
inhalation
A: Placebo Placebo Placebo
B: FF/VI AM FF (100 mcg)
/VI (25 mcg)
Placebo
C: FF/VI PM Placebo FF (100 mcg)
/VI (25 mcg)
Note: FF/VI 100/25 represents an emitted dose from the DPI of
FF/VI 92/22 mcg.
FF Z Fluticasone Furoate; VI Z Vilanterol; AM Z morning;
PM Z evening; DPI Z dry powder inhaler.using electronic meters (ePEF meter, Jaeger Asthma
Monitor plus [AM2þ]). Morning and evening PEF was
measured prior to any study treatment or rescue medica-
tion from the start of the run-in period through completion
of Treatment Period 3.
Safety
The following safety assessments were performed: inci-
dence of adverse events (AEs) and serious AEs (SAEs); vital
signs; ECG and clinical laboratory tests (clinical chemistry,
haematology, urinalysis), oropharyngeal examination and
withdrawals due to worsening of asthma.Statistical methods
Sample size was based on feasibility. Approximately 24
subjects were planned to be enrolled to achieve 20 subjects
completing treatment and critical assessments. The ‘All
Subjects Population’, defined as all subjects who received
at least one dose of study medication, was the primary
population for all safety analyses. The intent-to-treat (ITT)
population, defined as the All Subjects Population who
provided at least one post-dose PEF or FEV1 assessment,
was the primary population for all efficacy analyses.
The primary endpoint, Day 14 FEV1 weighted mean
(0e24 h), was determined for each subject on each treat-
ment using the linear trapezoidal rule. A mixed effects
analysis of covariance (ANCOVA) model was fitted on Day 14
FEV1 weighted mean (0e24 h) with fixed effect terms for
treatment (morning, evening, placebo) and period, subject
baseline, period baseline, gender and age fitted as cova-
riates, and subject as a random effect. From these ana-
lyses, point estimates and their associated 95% confidence
intervals were constructed for each treatment. The dif-
ference between adjusted means and the corresponding
two-sided 90% confidence interval for morning dose versus
Figure 2 Mean FEV1 (95% CI) 0e24 h on Day 14 following administration of FF/VI 100/25 in the morning (AM) or evening (PM) and
placebo (Intent-to-Treat Population).
Table 2 Weighted mean FEV1 (mL; Day 14; 0e24 h) and
pre-treatment (trough) FEV1 (mL; Day 14; AM and PM):
statistical analysis (Intent-to-Treat Population).
Treatment Adjusted
means
test
Difference from
placebo (90% CI)
Difference from
FF/VI PM
(90% CI)
Day 14 weighted mean FEV1 (0e24 h)
FF/VI AM 3188 377 (293, 462) 44 (125, 36)
FF/VI PM 3233 422 (337, 507) NA
Placebo 2811 NA NA
Day 14 pre-treatment (trough) AM FEV1
FF/VI AM 3191 403 (272, 533) 94 (221, 34)
FF/VI PM 3285 496 (369, 624) NA
Placebo 2788 NA NA
Day 14 pre-treatment (trough) PM FEV1
FF/VI AM 3153 275 (169, 380) 34 (138, 70)
FF/VI PM 3188 309 (205, 413) NA
Placebo 2879 NA NA
FEV1 Z forced expiratory volume in 1 s; FF Z Fluticasone
Furoate; VI Z Vilanterol; AM Z morning; PM Z evening; NA Z
not applicable.
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evening doses was calculated and presented.
The same model was used for the analysis of secondary
efficacy endpoints, morning and evening pre-treatment
(trough) FEV1 on Day 14.
The secondary endpoint, mean pre-treatment morning
PEF on Days 2e12 was defined as the mean of the non-
missing PEF morning post-dose PEF values for each subject
on Days 2e12. A mixed effects analysis of covariance model
was fitted on pre-treatment morning PEF with fixed effect
terms for treatment and period, baseline morning PEF,
gender and age fitted as covariates, and subject as a
random effect. Evening pre-treatment PEF was calculated
similarly using evening PEF values and modelled using
baseline evening PEF. Safety data were listed and sum-
marised; no formal statistical analysis was performed.
Results
Subject demographics and disposition
Twenty six subjects were randomised into this study (18
males, 69%). The mean [range] for age was 38.1 years
[24e64], weight 76.3 kg [54.6e102.2], height 171.5 cm
[153e186] and BMI 25.9 kg/m2 [19.3e29.9]. The majority of
subjects were of white/Caucasian/European heritage
(96%). Mean [range] percentage predicted normal FEV1 was
80.25% [62.0e103]. Twenty four subjects (92%) completed.
Two subjects were prematurely withdrawn during Treat-
ment Period 1, one due to AEs (FF/VI 100/25 [evening
dose]) and one withdrew their consent for personal reasons
(FF/VI 100/25 [evening dose]). The most common
concomitant medications taken ‘on treatment’ were para-
cetamol (13 subjects) and ibuprofen (3 subjects) to treat
headaches, symptoms of common cold and menstrual
cramps. There were no withdrawals due to worsening
asthma or asthma AEs.Efficacy
The effect of once-daily FF/VI 100/25 administered
morning or evening compared with placebo on mean FEV1
recorded at 3-h intervals 0e24 h on Day 14 is shown in
Fig. 2. Both morning and evening dosing with FF/VI pro-
duced increases in FEV1 compared with placebo
throughout the 0e24 h period with no marked differences
between the two FF/VI treatment regimes. There was
little evidence of diurnal variation in FEV1 following either
morning or evening FF/VI treatment with no early morning
nadir as seen with placebo. Day 14 weighted mean FEV1
Figure 3 Mean PEF (95% CI) measured in the morning (AM) and evening (PM) on Days 1e14 of administration of FF/VI 100/25 (AM
or PM) and placebo (Intent-to-Treat Population).
Morning versus evening administration of FF/VI 18770e24 h (primary endpoint) was clinically significantly
greater than placebo after both morning and evening
dosing with FF/VI; the increases were 377 mL (90% CI: 293,
462) and 422 mL (90% CI: 337, 507), respectively (Table 2).
The difference in Day 14 weighted mean FEV1 (0e24 h)
between morning and evening dosing was small and not
clinically significant (44 mL; 90% CI: 125, 36). On Day
14, both morning and evening pre-treatment (trough) FEV1
were numerically higher with evening dosing compared
with morning dosing (morning:evening difference 94 mL
(90% CI: 221, 34) and 34 mL (90% CI: 138, 70),
respectively) (Table 2).
FF/VI dosed in the morning and evening produced in-
creases in pre-treatment PEF over 1e14 days compared
with placebo. Morning and evening PEF increased rapidly
after the first dose and was maintained throughout the 14-
day treatment period (Fig. 3). FF/VI 100/25 (morning and
evening) produced increases in mean pre-treatment PEF
(Days 2e12) compared with placebo (Table 3). Morning PEF
(Days 2e12) was greater after evening dosing compared
with morning dosing (25 L/min difference). However, eve-
ning PEF was similar following FF/VI dosed either in the
morning or evening (<4 L/min difference) (Table 3).Table 3 Pre-treatment PEF (L/min; Days 2e12; AM and PM): st
Measurement time Treatment Adjusted means t
Mean pre-treatment PEF (L/min) on Days 2e12
AM FF/VI AM 510.4
FF/VI PM 535.3
Placebo 466.3
PM FF/VI AM 517.6
FF/VI PM 521.4
Placebo 453.2
PEF Z peak expiratory flow; FF Z Fluticasone Furoate; VI Z VilanteSafety
Twenty subjects (77%) reported at least one AE during the
study with similar numbers across all treatments. The most
frequently reported AEs were headache (50%) and naso-
pharyngitis (23%) with similar numbers across the treat-
ments. One subject withdrew from the FF/VI 100/25
(evening) treatment period due to AEs of headache and
epistaxis; both were considered to be drug-related. The
overall incidence of AEs considered related to study drug
was low (35%) with the most frequently reported being
headache (23%). More subjects had drug-related AEs after
FF/VI (17% [morning], 20% [evening]) than placebo (9%).
There were no SAEs or deaths, no clinically significant
changes in the ECG, vital signs or clinical laboratory as-
sessments and no subjects had an asthma exacerbation
during the study.Discussion
The efficacy of FF/VI 100/25 was comparable when dosed
in the morning or evening in subjects with persistentatistical analysis (Intent-to-Treat Population).
est Difference from
placebo (90% CI)
Difference from
FF/VI PM (90% CI)
44.0 (31.2, 56.9) 25.0 (37.9, 12.0)
69.0 (55.9, 82.1) NA
NA NA
64.4 (52.9, 76.0) 3.7 (15.2, 7.7)
68.2 (56.5, 79.8) NA
NA NA
rol; AM Z morning; PM Z evening; NA Z not applicable.
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100/25 produced comparable increases in weighted mean
FEV1 (0e24 h on Day 14) which was the primary endpoint in
this study; the average differences from placebo were
377 mL (90% CI: 293, 462) and 422 mL (90% CI: 337, 507),
respectively. The mean difference from placebo for morn-
ing dosing compared with evening dosing was 44 mL (90%
CI: 125, 36), which was not clinically significant. These
data are consistent with results obtained from another
study in which FF/VI 100/25 significantly improved lung
function (weighted mean [0e24 h] and trough FEV1)
following once-daily evening dosing over 12 weeks in pa-
tients with persistent asthma [10]. FEV1, recorded at reg-
ular 3-h intervals (0e24 h) after dosing on Day 14, was
stable over the 24-h period following FF/VI 100/25 admin-
istration in either the morning or evening with no apparent
early morning nadir in lung function. On Day 14, the 0e24 h
FEV1 profiles were similar for both morning and evening
doses even though the final FF/VI evening dose was
administered at the 0 h time point (21:00) while the final
FF/VI morning dose was administered in the middle of the
0e24 h period at the 12-h time point (09:00). In contrast,
diurnal variation and an early morning nadir were seen in
the Day 14 (0e24 h) FEV1 profile following placebo
administration.
Day 14 pre-treatment FEV1, at both the morning and
evening time points, was greater than placebo after dosing
FF/VI either in the morning or evening. The differences
between morning and evening dosing were not clinically
significant. However, with evening dosing, the numerically
greater morning pre-treatment FEV1 (94 mL) may be
explained by the shorter time elapsed since dosing (i.e.
12 h versus 24 h). The greater evening pre-treatment FEV1
with evening dosing is less easy to understand although the
difference from morning dosing was only 34 mL.
In this study, clinical significance for improvements in lung
function was not defined a priori. However, the increases in
FEV1 seen after dosing FF/VI in the morning or evening were
greater than the 230mL threshold that has been described as
the ‘minimal patient perceivable improvement’ when
measuring lung function in asthma patients [28]. This value
was derived using the framework developed by Jaeschke
which compared spirometry changes with those of patient
reported outcomes in order to investigate the clinical
meaning of improvements in lung function [29].
The PEF data were similar to the FEV1 results. Mean pre-
treatment morning and evening PEF recorded on Days 1e14
was greater after FF/VI, dosed either in the morning or
evening, compared with placebo. The increases in PEF were
rapid in onset with the full effect seen after the first dose
and this was maintained throughout the 14-day treatment
period. As for the FEV1 measurements, the improvements
seen in the morning or evening PEF measurements following
morning or evening dosing with FF/VI may all be considered
to be clinically significant as they exceeded a change in PEF
of 18.79 L/min which represents a patient perceivable in-
crease [28]. Similar to the Day 14 pre-treatment FEV1,
mean morning PEF (Days 2e12) relative to placebo was
greater after evening dosing compared with morning dosing
(25 L/min difference), probably reflecting the shorter time
elapsed since treatment administration (12 h versus 24 h).
In contrast, mean evening PEF (Days 2e12), compared withplacebo, was similar following FF/VI dosed either in the
morning or evening (<4 L/min difference) despite the
morning dose being given within 12 h of the evening PEF
measurement; the reasons for this are unknown.
Currently licensed ICS/LABA combinations are adminis-
tered twice-daily and, to our knowledge, this is the first
study comparing the efficacy of morning and evening dosing
with a once-daily ICS/LABA. However, the effect of time of
day of dosing on the efficacy of LABAs and ICS therapies
when administered separately have been studied. Indaca-
terol is the only available once-daily LABA and produces
comparable bronchodilation whether dosed in the morning
or evening in COPD patients [30].
Most of the ICS therapies presently prescribed for
asthma are indicated for twice-daily dosing. However,
double-blind studies in asthma have been published that
compare once-daily evening and morning administration of
ICS, including budesonide, ciclesonide (both of which are
licensed for twice-daily administration) and mometasone
furoate (licensed for once-daily administration), and show
that evening dosing is at least as effective or more effective
than morning dosing in terms of improvements in lung
function [23,24,31]. More recently, once-daily evening
administration of FF 400 in patients with mild to moderate
asthma produced statistically significant placebo-adjusted
improvements in evening pre-dose FEV1 following 8 weeks
of treatment, which was comparable with FF 200 mcg
administered twice daily (240 mL vs 235 mL) [22]. Once-
daily morning administration of FF 400 was also effective
although it resulted in a smaller improvement in lung
function (morning pre-dose FEV1) compared with FF
200 mcg twice daily (315 mL vs 202 mL) thus demonstrating
that morning or evening dosing of FF/VI is possible [22].
A formal analysis for a carryover effect was not tested in
the study. However, summaries of the baseline FEV1 by
period mean [95% CI] values showed that they were very
similar (2.860 L [2.607, 3.114], 2.860 L [2.550, 3.170] and
2.889 L [2.534, 3.243] for Treatment Periods 1, 2 and 3,
respectively). Furthermore, the effect of period baseline in
the statistical model was not significant. Consequently there
was no suggestion that the treatment effect seen throughout
the 14-day treatment period was still present and affecting
the baseline FEV1 values for each subsequent period and that
a significant carryover effect was present. A previous study
showed that following four weeks’ treatment with the
inhaled corticosteroids FP or budesonide, lung function
(FEV1) rapidly returned to baseline within one week of the
cessation of treatment [32]. Furthermore, the interval be-
tween treatments for the primary endpoint (weighted mean
FEV1) on Day 14 was effectively approximately 28 days (i.e.
14-day washout and 14-day treatment period).
Considerable evidence suggests that circadian rhythms
influence disease manifestations in asthma with enhanced
bronchial responsiveness seen at night-time regardless of
whether patients have worsening of asthma symptoms or
lung function [15,19,21]. Evaluating the effectiveness of
bronchodilators at different times of the day is indispens-
able given the marked circadian variation in asthma
symptoms; many studies have demonstrated an advantage
in managing patients with primarily nocturnal symptoms
with the administration of once-daily bronchodilators at
night [18]. Similarly, the time of administration of
Morning versus evening administration of FF/VI 1879corticosteroids has been considered critical for optimising
anti-inflammatory treatment [15,17,19] e with a conse-
quent alleviation of night-time symptoms [19e21,33].
Serum cortisol also follows a circadian rhythm, with peak
concentrations seen in the early morning and trough con-
centrations at night [25]. Some studies have shown a
greater effect on cortisol when corticosteroids are dosed in
the morning compared with the evening, thus indicating
that evening dosing of ICS may be the optimal time of
administration [25,34]. However, in subjects with asthma
FF at doses up to 600 mcg (evening dosing) had no effects
on 24-h urine cortisol excretion [35]. There was also no
effect of FF 200 and 400 mcg dosed either morning or
evening on 24-h urine cortisol excretion in subjects with
asthma [22]. FF/VI 100/25 and 200/25 did not produce
significant effects on 24-h weighted mean serum cortisol or
on 24-h urine cortisol excretion in subjects with asthma
(evening dosing) [36]. Similarly, in subjects with COPD FF/
VI at doses up to 200/25 mcg (morning dosing) was not
associated with statistically or clinically significant effects
on 24-h serum cortisol [14] or on 24-h urine cortisol
excretion [37]. These studies clearly demonstrate the lack
of significant cortisol effects of FF at doses considerably
above the 100 mcg therapeutic dose examined in this study.
Based on these data it was considered unlikely that FF/VI
100/25 mcg, administered either morning or evening,
would affect adrenal function in subjects with asthma and
consequently cortisol was not investigated in this study.
Therefore, the data from the current study supports the
concept that FF/VI can be dosed in the morning or evening,
which may prove beneficial to patients by providing a
convenient and flexible dosing regimen to manage their
asthma symptoms as well as fit around their lifestyle.
Repeat-dose (14  2 days) FF/VI 100/25 was well-
tolerated when dosed morning or evening, with similar
numbers of AEs in the active and placebo groups; no safety
concerns were raised.
One of the key strengths of this study is that a thorough
assessment of lung function was conducted over 24 h on Day
14, and on every day throughout the treatment and washout
periods. A potential limitation of the current study is that
while the sample size (24 subjects) was sufficient to provide
an indication of the effect of dosing time on the efficacy of
FF/VI 100/25 in asthma, a much larger study would be
required to make confirmatory claims regarding equivalence
of morning and evening dosing. However, weighted mean
FEV1 [standard deviation] summary statistics formorning and
evening dosing (3.250 L [0.7832] and 3.303 L [0.7510],
respectively) showed similar data distributions suggesting
similar efficacy between the two dosing regimens.
Conclusion
FF/VI 100/25 produces comparable improvements in lung
function whether dosed in the morning or evening in sub-
jects with persistent asthma.
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